Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

Clinical trial NCT02226757 · UNKNOWN

Trial details

NCT number: NCT02226757
Sponsor: Amsterdam UMC, location VUmc
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC HER2-expression EGFR-mutation

Start date: 2014-08-01
Primary completion: 2016-08-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.